Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS).

被引：0
|
作者：
Pietzner, Klaus
Vergote, Ignace
Santoro, Armando
Marme, Frederik
Rosenberg, Per
Friccius-Quecke, Hilke
Sehouli, Jalid
机构：
[1] Charite, D-13353 Berlin, Germany
[2] UZ Leuven, Louvain, Belgium
[3] Ist Clin Humanitas, Humanitas Canc Ctr, Rozzano, Italy
[4] Univ Heidelberg Hosp, Dept Obstet & Gynecol, Heidelberg, Germany
[5] NSGO, Linkoping, Sweden
[6] Linkoping Univ Hosp, Onkol Kliniken Univ Sjukhuset, S-58185 Linkoping, Sweden
[7] Fresenius Biotech GmbH, Munich, Germany
[8] Charite Campus Virchow Klinikum, European Competence Ctr Ovarian Canc, Dept Gynecol, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5582
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer A Phase II Study
    Berek, Jonathan S.
    Edwards, Robert P.
    Parker, Lynn P.
    DeMars, Leslie R.
    Herzog, Thomas J.
    Lentz, Samuel S.
    Morris, Robert T.
    Akerley, Wallace L.
    Holloway, Robert W.
    Method, Michael W.
    Plaxe, Steven C.
    Walker, Joan L.
    Friccius-Quecke, Hilke
    Krasner, Carolyn N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1583 - 1589
  • [22] Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
    Ott, Marion G.
    Marme, Frederik
    Moldenhauer, Gerhard
    Lindhofer, Horst
    Hennig, Michael
    Spannagl, Rolf
    Essing, Mirko M.
    Linke, Rolf
    Seimetz, Diane
    INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (09) : 2195 - 2203
  • [23] Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study
    Jaeger, M.
    Schoberth, A.
    Theissen, B.
    Hess, J.
    Friccius-Quecke, H.
    Lindhofer, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Quality of Life in Patients With Malignant Ascites and Ascites Symptoms After Treatment With Catumaxomab: Results From a Multicenter Phase II/III Study Comparing Paracentesis Plus Catumaxomab With Paracentesis Alone
    Gonschior, A.
    Gilet, H.
    Heisss, M. M.
    Hennig, M.
    Moehler, M.
    Schmalfeldt, B.
    Schulze, E.
    Wimberger, P.
    Parsons, S. L.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S223 - S223
  • [25] Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: Results of a phase I/II trial
    Sabbatini, P
    Aghajanian, C
    Leitao, M
    Venkatraman, E
    Anderson, S
    Dupont, J
    Dizon, D
    O'Flaherty, C
    Bloss, J
    Chi, D
    Spriggs, D
    CLINICAL CANCER RESEARCH, 2004, 10 (09) : 2962 - 2967
  • [26] Quality of life in patients with malignant ascites and after treatment with catumaxomab: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone
    Schmalfeldt, B.
    Seck, K.
    Gonschior, A. K.
    Gilet, H.
    Heiss, M.
    Hennig, M.
    Moehler, M.
    Schulze, E.
    Wimberger, P.
    Parsons, S. L.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2012, 72 (04)
  • [27] PROGNOSTIC FACTORS FOR THE EFFICACY OF CATUMAXOMAB IN PATIENTS WITH MALIGNANT ASCITES (MA) DUE TO OVARIAN CANCER (OC): META-ANALYSIS FROM TWO PHASE III STUDIES
    Sehouli, J.
    Heiss, M.
    Lordick, F.
    Parsons, S. L.
    Wimberger, P.
    Marschner, A.
    Wagner, U.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [28] MAINTENANCE OF QUALITY OF LIFE IN PATIENTS WITH MALIGNANT ASCITES DURING TREATMENT WITH THE TRIFUNCTIONAL ANTIBODY CATUMAXOMAB: RESULTS FROM THE PHASE III B CASIMAS TRIAL
    Lordick, F.
    Sehouli, J.
    Vergote, I. B.
    Rosenberg, P.
    Schneeweiss, A.
    Block, A.
    Salat, C.
    Scambia, G.
    Berton-Rigaud, D.
    Wimberger, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 514 - 514
  • [29] The role of relative lymphocyte counts for the effect of catumaxomab on overall survival in ovarian cancer patients with malignant ascites: Results from a phase 11/111 trial
    Heiss, M.
    Tschirschmann, M.
    Seimetz, D.
    Stroehlein, M.
    Hennig, M.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S88 - S88
  • [30] A PHASE-II TRIAL OF INTRAPERITONEAL CISPLATIN AND ETOPOSIDE FOR PRIMARY-TREATMENT OF OVARIAN EPITHELIAL CANCER
    HOWELL, SB
    KIRMANI, S
    LUCAS, WE
    ZIMM, S
    GOEL, R
    KIM, S
    HORTON, MC
    MCVEY, L
    MORRIS, J
    WEISS, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) : 137 - 145
12345